Hope for Duchenne Patients: Swedish Cell Therapy Subsidiary Enters U.S. Market Following Licensing Agreement
STOCKHOLM, Sweden – 27.11.2025 – CarryGenes Therapeutics AB today announced that its subsidiary CG Bioengineering (CGB) has signed an exclusive and significant licensing agreement with U.S.-based EIRx Biologics Inc. The agreement covers the development of a new, potentially life-changing cell therapy for the serious disease Duchenne Muscular Dystrophy (DMD), based on CarryGenes' unique hSynC technology. This technology has the capacity to carry significantly larger amounts of genetic material compared to current vector methods, opening the possibility to develop even more effective